These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 7612899)

  • 41. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
    Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
    Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
    Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
    Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overexpression of mitogen-activated protein kinase superfamily proteins unrelated to Ras and AF-1 of estrogen receptor alpha mutation in advanced stage human breast cancer.
    Hori M; Inagawa S; Shimazaki J; Itabashi M; Hori M
    Pathol Res Pract; 2000; 196(12):817-26. PubMed ID: 11156322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose-dependent mutation profile in the c-Ha-ras proto-oncogene of skin tumors in mice initiated with benzo[a]pyrene.
    Wei SJ; Chang RL; Merkler KA; Gwynne M; Cui XX; Murthy B; Huang MT; Xie JG; Lu YP; Lou YR; Jerina DM; Conney AH
    Carcinogenesis; 1999 Sep; 20(9):1689-96. PubMed ID: 10469612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutations in PIK3CA are infrequent in neuroblastoma.
    Dam V; Morgan BT; Mazanek P; Hogarty MD
    BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
    Thompson KN; Whipple RA; Yoon JR; Lipsky M; Charpentier MS; Boggs AE; Chakrabarti KR; Bhandary L; Hessler LK; Martin SS; Vitolo MI
    Oncotarget; 2015 Nov; 6(34):35231-46. PubMed ID: 26497685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.
    Kiessling MK; Rogler G
    Swiss Med Wkly; 2015; 145():w14207. PubMed ID: 26691679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of liver oncogenic potential among human RAS isoforms.
    Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
    Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bcl-2 associates with the ras-related protein R-ras p23.
    Fernandez-Sarabia MJ; Bischoff JR
    Nature; 1993 Nov; 366(6452):274-5. PubMed ID: 8232588
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting RAS signalling pathways in cancer therapy.
    Downward J
    Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.
    Tsujioka H; Hachisuga T; Fukuoka M; Ueda T; Miyahara D; Horiuchi S; Shirota K; Yoshizato T; Emoto M; Miyamoto S; Kawarabayashi T
    Int J Gynecol Cancer; 2009 Aug; 19(6):1052-6. PubMed ID: 19820367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ras-mediated up-regulation of survivin expression in cytokine-dependent murine pro-B lymphocytic cells.
    Shinjyo T; Kurosawa H; Miyagi J; Ohama K; Masuda M; Nagasaki A; Matsui H; Inaba T; Furukawa Y; Takasu N
    Tohoku J Exp Med; 2008 Sep; 216(1):25-34. PubMed ID: 18719335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase.
    Lee J; Choi KJ; Lim MJ; Hong F; Choi TG; Tak E; Lee S; Kim YJ; Chang SG; Cho JM; Ha J; Kim SS
    Cell Res; 2010 Aug; 20(8):919-34. PubMed ID: 20603646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.
    Lim KH; Counter CM
    Cancer Cell; 2005 Nov; 8(5):381-92. PubMed ID: 16286246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The ras signaling pathway in mammary tumorigenesis and metastasis.
    Malaney S; Daly RJ
    J Mammary Gland Biol Neoplasia; 2001 Jan; 6(1):101-13. PubMed ID: 11467446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting.
    Shu L; Wang D; Saba NF; Chen ZG
    Mol Cancer Ther; 2020 Apr; 19(4):999-1007. PubMed ID: 32241873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oncogenic signaling pathways and deregulated target genes.
    Schäfer R; Schramme A; Tchernitsa OI; Sers C
    Recent Results Cancer Res; 2007; 176():7-24. PubMed ID: 17607912
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.
    Watanabe S; Otani T; Iwasa T; Takahama T; Takeda M; Sakai K; Nishio K; Ito A; Nakagawa K
    Clin Breast Cancer; 2019 Oct; 19(5):e589-e592. PubMed ID: 31301988
    [No Abstract]   [Full Text] [Related]  

  • 60. The Ins and Outs of RAS Effector Complexes.
    Kiel C; Matallanas D; Kolch W
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33562401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.